Use of corticosteroids doubled the risk (HR 2.28, 95% CI 1.87 to 2.79, P<0.0001), while methotrexate use halved the risk (HR 0.54, 95% CI 0.39 to 0.74, P=0.0001). For all-cause mortality, each month since stopping statins was associated with a 1% increase in risk (HR 1.010, 95% CI 1.002 to 1.015). "By demonstrating the impact of statin discontinuation for specific [cardiovascular disease] mortality and all-cause mortality outcomes, our study suggests the importance of ensuring compliance with statin treatment among [rheumatoid arthritis] patients prescribed statins," stated De Vera and colleagues. Mechanisms by which statins could influence mortality in patients with rheumatoid arthritis include effects on cholesterol, as well as immune modulation and anti-inflammatory effects. Limitations of the study included its reliance on administrative data, the possibility of inaccuracies in diagnosis, and a lack of information on whether medication was actually taken. Strengths were its population-based design, which can minimize selection bias, and completeness of data on medications prescribed. The researchers concluded that their findings "provide support for raising awareness among health professionals and people with [rheumatoid arthritis] of the importance of therapy compliance among patients prescribed statins." Primary source: Arthritis Care & Research Source reference: De Vera M, et al “Impact of statin discontinuation on mortality in patients with rheumatoid arthritis - a population-based study” Arthritis Care Res 2012; DOI: 10.1002/acr.21643.